Polymer lipid compounds, and compositions, preparation and use thereof
By developing polymer lipid compounds based on bile acid derivatives, the problem of naked RNA's difficulty in entering cells has been solved, enabling efficient delivery of nucleic acid drugs and providing more delivery options suitable for nucleic acid drugs, gene vaccines, peptides, proteins, and small molecule drugs.
Patent Information
- Application Number
- PCT/CN2024/092610
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-11
- Filing Date
- 2024-05-11
- Publication Date
- 2024-11-14
AI Technical Summary
Naked RNA is difficult to enter cells and is easily degraded by RNases in vivo. Existing lipid nanoparticles (LNPs) have problems with hydrophilicity and large size during assembly, resulting in low delivery efficiency.
Develop polymeric lipid compounds based on bile acids or their derivatives, and form novel lipid nanoparticles by modifying PEG chains and other lipid components to improve cellular uptake and delivery efficiency.
It improves the delivery efficiency of nucleic acid drugs, prolongs in vivo circulation time, reduces production costs, and provides more delivery options, applicable to nucleic acid drugs, gene vaccines, peptides, proteins, and small molecule drugs.
Smart Images

Figure CN2024092610_14112024_PF_FP_ABST
Abstract
Description
Polymer lipid compounds and their compositions, preparation and use
[0001] This application claims the patent "Lipid compounds and their compositions, preparation and use" (application number: 2023105292749) and the patent "Dipeptide lipid compounds, preparation methods and lipid nanoparticles, pharmaceutical compositions" (application number: 202410048423.4), all of which lipid compounds in the prior applications are hereby incorporated by reference in their entirety. Technical Field
[0002] The present invention relates to the field of biomedicine technology, and specifically to a class of polymer lipid compounds and their compositions, preparation and uses, especially their use in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs. Background Art
[0003] Nucleic acid drugs refer to artificially designed DNA or RNA molecules with disease prevention or treatment capabilities. They act on target genes or mRNAs, regulating the expression of pathogenic genes at the source, thereby achieving the goal of disease prevention or treatment. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs can inhibit pathological proteins at the source, offering advantages such as significant efficacy, rapid production, strong target specificity, and a short development cycle. Nucleic acid drugs primarily include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA (miRNA), and messenger RNA (mRNA). As of the end of 2021, the FDA had approved over 10 nucleic acid drugs, with several candidate drugs in clinical trials or preclinical testing. The FDA has already approved the RNA vaccines BNT162b2 (Pfizer / BioNTech) and mRNA-1273 (Moderna) for the prevention of COVID-19. Several COVID-19 vaccines based on mRNA technology are also in clinical trials or preclinical testing in my country. In the fight against the COVID-19 pandemic, mRNA technology has demonstrated its unique advantages over traditional biopharmaceutical and vaccine technologies.
[0004] However, naked RNA is a negatively charged, hydrophilic macromolecule that has difficulty entering cells due to electrostatic repulsion from cell membranes and is readily degraded by RNases in the body. Therefore, a delivery vehicle is required for entry into cells. Lipid nanoparticles (LNPs) have been successfully used as a delivery platform for RNA vaccines and therapies.
[0005] Polymer-modified lipids (e.g., PEG lipids) are an important component in LNPs for regulating half-life and cellular uptake. When LNPs are assembled, PEG chains are located on the outer shell of the nanoparticles due to their hydrophilicity and large size. Like other nanocarriers, PEG provides an external polymer layer for LNPs to prevent serum protein adsorption and uptake by the mononuclear phagocyte system, thereby extending circulation time in the body. PEG can also prevent aggregation of nanoparticles during storage and in the blood. In addition, the amount of PEG lipids may determine the size of the particles. Another potential purpose of PEG lipids is to achieve surface functionalization of LNPs. Functionalized PEG lipids can biocouple LNPs with ligands or biomacromolecules.
[0006] The present invention develops a new polymer lipid, which provides a new delivery carrier for nucleic acid drugs.
[0007] Summary of the Invention
[0008] The present invention provides a new class of polymer lipid compounds for delivering therapeutic or preventive drugs, namely polymer lipids based on bile acid or its derivatives, which enrich the types of polymer lipid compounds and provide more options for the delivery of nucleic acid drugs, gene vaccines, peptides, proteins, antibodies and small molecule drugs.
[0009] In one aspect, the present invention provides a polymer lipid compound of the following general formula, or a pharmaceutically acceptable salt thereof, including stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs. Specifically, the "pharmaceutically acceptable salt thereof" refers to an acid addition salt or a base addition salt; the general formula is as follows:
[0010] R1 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl,
[0011] Alkanes containing nitrogen atoms, alkenes containing nitrogen atoms, alkanes containing oxygen atoms
[0012] R2 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl,
[0013] Alkanes containing nitrogen atoms, alkenes containing nitrogen atoms, alkanes containing oxygen atoms
[0014] R3 = hydroxyl group, halogen atom, alkane, alkene, alkyne
[0015] R4=hydrogen atom, small molecules, antibodies, peptides, proteins, nucleic acids, carbohydrates
[0016] X = PEG (polyethylene glycol), polysarcosine derivatives, chitosan derivatives, hyaluronic acid derivatives, dextran, polylactic acid, polyamino acid-modified phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, dialkylglycerol
[0017] L1, L2 = the same or different, linear / branched alkyl chains or heterocyclic compounds, with one or more of amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphoric acid, and carbonate groups at both ends
[0018] Specifically, the polymer lipid compound is a polymer lipid based on bile acid or its derivatives; wherein bile acid or its derivatives are selected from cholic acid, obeticholic acid, ursodeoxycholic acid, ursolic acid, 3β-hydroxy-D5-cholenic acid, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, taurocholic acid, 5β-cholic acid, dehydrocholic acid, hyrocholic acid, cholic acid, glycochenodeoxycholic acid, tauroursodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium taurohyodeoxycholate, sodium dehydrocholate, sodium cholate, sodium deoxyglycocholate, sodium taurodeoxycholate, sodium taurocholate, sodium taurochenodeoxycholate, glycocholic acid sodium salt, taurocholic acid-3-sulfate disodium salt, sodium tauroursodeoxycholate and sodium taurolithocholic acid.
[0019] Specifically, the lipid compound is ursodeoxycholic acid or its derivatives, or lithocholic acid or its derivatives.
[0020] Specifically, the lipid compound is selected from one or more ursodeoxycholic acid derivative lipid compounds, or one or more obeticholic acid derivative lipid compounds, one or more cholic acid derivative lipid compounds, one or more hyodeoxycholic acid derivative lipid compounds, and one or more chenodeoxycholic acid derivative lipid compounds.
[0021] Specifically, the molecular weight of the polymer in the polymer lipid compound is 200-20,000 Daltons.
[0022] Specifically, the polymer in the polymer lipid compound can be a branched molecule or a linear molecule.
[0023] Specifically, the two ends of the polymer in the polymer lipid compound can be one or more of methoxy, amino, carboxyl, hydroxyl, sulfhydryl, sulfate, sulfonic acid, and phosphate groups.
[0024] The linking molecules (L1, L2) in the polymer lipid compound are identical or different from each other and are independently selected from: not present, or one or more of the following structures; in addition, the linking molecules (L1, L2) are connected to both ends via one or more of an ester group, an amide group, a carbamate group, a carbonate group, an ether group or a urea group.
[0025] Specifically, L1 and L2 are independently selected from a linear saturated hydrocarbon or unsaturated hydrocarbon with 2-25 carbon atoms, and one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups at both ends.
[0026] Specifically, L1 and L2 are independently selected from saturated hydrocarbons or unsaturated hydrocarbons containing 3-8 membered rings, and both ends of the hydrocarbons are one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups.
[0027] Wherein, R4 in the polymer lipid compound can be independently selected from one or more of nucleic acids, small molecules, carbohydrates, antibodies, peptides or other ligands.
[0028] Specifically, the polypeptide includes but is not limited to targeting peptides, protease inhibitors, and the like. Further preferably, the targeting peptide includes but is not limited to GALA peptide, and the like. Still further preferably, the GALA peptide is a targeting peptide consisting of 30 amino acids, the sequence of which is: WEAALAEALAEALAEHLAEALAEALEALAA. Further preferably, the protease inhibitor is a FAP inhibitor (FAPI).
[0029] The present invention also provides a polymer lipid compound, wherein the polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure:
[0030] R1 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl,
[0031] Alkanes containing nitrogen atoms, alkenes containing nitrogen atoms, alkanes containing oxygen atoms
[0032] R2 = hydrogen atom, alkyl group, alkene, alkyne, substituted carbonyl group, alkane containing nitrogen atom, alkene containing nitrogen atom
[0033] R3 = hydroxyl group, chlorine atom, alkane, alkene, alkyne
[0034] R4=hydrogen atom, small molecules, antibodies, peptides, proteins, nucleic acids, carbohydrates
[0035] X = PEG (polyethylene glycol), polysarcosine derivatives, chitosan derivatives, dextran, polylactic acid, polyamino acid-modified phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, dialkylglycerol
[0036] L1, L2 = the same or different, linear / branched alkyl chains or heterocyclic compounds, with one or more of amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphoric acid, and carbonate groups at both ends.
[0037] Specifically, the polymer lipid compound is a polymer lipid based on bile acid or its derivatives; wherein bile acid or its derivatives are selected from one or more of 3β-hydroxy-D5-cholenic acid, lithocholic acid, deoxycholic acid, 5β-cholic acid, dehydrocholic acid, cholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium taurohyodeoxycholate, sodium dehydrocholate, sodium deoxyglycocholate, sodium taurodeoxycholate, taurocholic acid-3-sulfate disodium salt and sodium taurolithocholic acid.
[0038] Specifically, the lipid compound is lithocholic acid or a derivative thereof.
[0039] Specifically, the lipid compound is one or more selected from bile acid derivative lipid compounds and one or more hyodeoxycholic acid derivative lipid compounds.
[0040] Specifically, the molecular weight of the polymer in the polymer lipid compound is 200-20,000 Daltons.
[0041] Specifically, the polymer in the polymer lipid compound can be a branched molecule or a linear molecule.
[0042] Specifically, the two ends of the polymer in the polymer lipid compound can be one or more of methoxy, amino, carboxyl, hydroxyl, sulfhydryl, sulfate, sulfonic acid, and phosphate groups.
[0043] The linking molecules (L1, L2) in the polymer lipid compound are identical or different from each other and are independently selected from: not present, or one or more of the following structures; in addition, the linking molecules (L1, L2) are connected to both ends through one or more of an ester group, an amide group, a carbamate group, a carbonate group, an ether group or a urea group.
[0044] Specifically, L1 and L2 are independently selected from a linear saturated hydrocarbon or unsaturated hydrocarbon with 2-25 carbon atoms, and one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups at both ends.
[0045] Specifically, L1 and L2 are independently selected from saturated hydrocarbons or unsaturated hydrocarbons containing 3-8 membered rings, and both ends of the hydrocarbons are one or more of carboxyl groups, hydroxyl groups, amino groups, sulfate groups, sulfonic acid groups, and phosphoric acid groups.
[0046] Wherein, R4 in the polymer lipid compound can be independently selected from one or more of nucleic acids, small molecules, carbohydrates, antibodies, peptides or other ligands.
[0047] In another aspect, the present invention also provides a polymer-lipid compound conjugate, which is primarily composed of a therapeutic or preventive drug, a linker, and a lipid compound as described in any of the patents. The therapeutic or preventive drug includes nucleic acids, proteins, polypeptides, antibodies, carbohydrates, small molecule compounds, and the like.
[0048] Specifically, the nucleic acid of the therapeutic or preventive drug includes DNA and RNA, wherein the DNA can be non-coding DNA or coding DNA, and the RNA can be selected from one or more of: ASO, mRNA, siRNA, and micRNA.
[0049] On the other hand, the present invention also provides a method for preparing the polymer lipid compound, which may include a step of reacting with RXY, wherein X, R and Y have the corresponding definitions in the polymer lipid compound scheme of the present invention, and R and Y are reactive groups, for example, hydroxyl, carboxyl, amino, thiol, maleimide, succinimide, alkynyl, azido, aldehyde, epoxy, etc.
[0050] In another aspect, the present invention also provides a composition of a polymer lipid compound, which comprises the polymer lipid compound described in the above technical solution or a pharmaceutically acceptable salt, ester, isomer, prodrug and solvate thereof.
[0051] Specifically, the composition includes a therapeutic or preventive agent and a carrier for delivering the therapeutic or preventive agent, and the carrier includes one or more of any polymer lipid compound or its conjugate described in this patent.
[0052] Specifically, the therapeutic or prophylactic agent is encapsulated within or associated with a carrier.
[0053] Specifically, the mass ratio of the carrier to the therapeutic or preventive agent is 1:1 to 100:1.
[0054] Specifically, the therapeutic or preventive agent includes one or more of nucleic acid molecules, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.
[0055] Specifically, the composition is lipid nanoparticles, the average size of the lipid nanoparticles is 20nm to 1000nm; and the polydispersity coefficient of the lipid nanoparticles is ≤0.3.
[0056] Specifically, the nucleic acid includes any form of nucleic acid molecules, including but not limited to single-stranded DNA, double-stranded DNA, short isomers, agomir, antagomir, antisense molecules, small interfering RNA (siRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), Dicer-substrate RNA (dsRNA), small hairpin RNA (shRNA), transfer RNA (tRNA), messenger RNA (mRNA) and other forms of RNA molecules known in the art, or nucleic acid mimics such as locked nucleic acid (LNA), peptide nucleic acid (PNA) and morpholino oligonucleotides.
[0057] According to some specific embodiments, the therapeutic or preventive agent comprises at least one mRNA encoding an antigen, protein, or peptide, or a fragment or epitope thereof.
[0058] In particular, the mRNA is a monocistronic mRNA or a polycistronic mRNA.
[0059] In particular, the antigen is a pathogenic antigen.
[0060] Specifically, the mRNA contains one or more functional nucleotide analogs, including but not limited to one or more of pseudouridine, 1-methyl-pseudouridine and 5-methylcytosine.
[0061] Specifically, the small molecule compounds include but are not limited to active ingredients of therapeutic and / or preventive agents, which are currently known drugs, such as anti-tumor drugs, anti-infective drugs, local anesthetics, antidepressants, anticonvulsants, antibiotics / antibacterial agents, antifungals, antiparasitic drugs, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-glaucoma agents, anesthetics, or contrast agents.
[0062] Specifically, the carrier comprises at least two different lipid components, wherein at least one of the lipids is a lipid based on bile acid or a derivative thereof.
[0063] Specifically, the carrier also includes one or more of cationic lipids or ionizable lipids, neutral lipids, and steroidal lipids. Specifically, the cationic lipids include but are not limited to 4-(N,N-dimethylamino)butyric acid (dilinoleyl) methyl ester (Dlin-MC3-DMA), 2-di-octadecanoyl-3-trimethylammonium-propane (DOTAP), 8-[(2-hydroxyethyl)[6-oxo-6-(undecyloxy)hexyl]amino]octanoic acid 1-octylnonyl ester (SM-102), dimethyldi-octadecanoate (DDAB), 3β-[N-(N',N'-dimethylaminoethane)-carbamoyl]cholesterol (DC-chol), 1,2-di-tetradecanoyl-3-trimethylammonium-propane (DMTAP), One or more of 1,2-di-(9Z-octadecenoyl)-3-dimethylammonium-propane (DODAP), 1,2-dioleoyl-c-(4'-trimethylammonium)-butyryl-sn-glycerol (DOTB), di-octadecylamino-alanylspermine, SAINT-2, the polycationic lipid 2,3-dioleoyloxy-N-[2(spermine-carboxamido)ethyl]-N,N-dimethyl-1-propanium trifluoroacetate (DOSPA), ((4-hydroxybutyl)azadialkyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), or derivatives thereof, particularly ALC-0315.
[0064] Specifically, the composition may further comprise neutral lipids, including but not limited to distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), , dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphatidylethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE) or mixtures thereof, in particular DSPC.
[0065] Specifically, the composition may further comprise steroidal lipids, including but not limited to avenasterol, β-sitosterol, brassicasterol, ergocalciferol, campesterol, cholestanol, cholesterol, coprosterol, dehydrocholesterol, streptosterol, dihydroergocalciferol, dihydrocholesterol, dihydroergosterol, melanosterol, epicholesterol, ergosterol, fuccasterol, hexahydroluminosterol, hydroxycholesterol; lanosterol, luminosterol, alginosterol, sitostanol, sitosterol, stigmasterol, stigmasterol, bile acid, glycocholic acid, taurocholic acid, deoxycholic acid and lithocholic acid, in particular cholesterol.
[0066] Specifically, the carrier also includes but is not limited to cationic lipids or ionizable lipids, neutral lipids and steroidal lipids; the molar ratio of the cationic lipids or ionizable lipids, neutral lipids, steroidal lipids and the polymer lipid compound of the present invention is (30-80): (5-20): (30-50): (0.2-5), and further preferably, the molar ratio of the cationic lipids or ionizable lipids, neutral lipids, steroidal lipids and the polymer lipid compound of the present invention is (45-55): (7-12): (35-45): (1-2).
[0067] Specifically, the mass ratio of the carrier to the therapeutic or preventive agent is 5:1 to 50:1. Further preferably, the mass ratio of the carrier to the therapeutic or preventive agent is 5:1 to 35:1. Even more preferably, the mass ratio of the carrier to the therapeutic or preventive agent is 10:1 to 30:1.
[0068] Specifically, the composition further comprises one or more pharmaceutically acceptable excipients or diluents.
[0069] Specifically, the composition further comprises one or more of a buffer, a carbohydrate, mannitol, a protein, a polypeptide or an amino acid, an antioxidant, an antibacterial agent, a chelating agent, and an adjuvant.
[0070] On the other hand, the present invention also provides a use of any lipid compound, conjugate or composition thereof in the preparation of nucleic acid drugs, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.
[0071] Specifically, any lipid compound, conjugate or composition thereof of this patent is used in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, wherein the composition is a lipid nanoparticle having a particle size of 20 to 1000 nm.
[0072] In another aspect, the present invention also provides the preparation of the polymer lipid compound or its pharmaceutically acceptable salt, ester, isomer, prodrug and solvate, the conjugate or the composition in a delivery system for therapeutic or preventive agents.
[0073] Specifically, the invention relates to a composition for preparing nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, which comprises a nucleic acid and a composition for encapsulating the nucleic acid, wherein the composition is a lipid nanoparticle, wherein each individual lipid nanoparticle comprises a plurality of lipid components, wherein one or two lipid components are bile acid-based lipid compounds, including compounds thereof or pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs thereof, and wherein the lipid nanoparticles have a nucleic acid encapsulation ratio of at least 70%.
[0074] In some embodiments, the lipid nanoparticles are formed by mixing an mRNA solution with a lipid solution of any polymer lipid compound of the present invention or a lipid solution of a conjugate thereof. In some embodiments, the lipid nanoparticles are further purified by tangential flow filtration.
[0075] Specifically, the lipid nanoparticles are formed by mixing an mRNA solution and a lipid solution. The medium of the mRNA solution is HEPES (hydroxyethylpiperazine ethanesulfonic acid buffer), phosphate, acetate, ammonium sulfate, sodium bicarbonate, or citrate. The medium of the lipid solution is ethanol, isopropanol, or dimethyl sulfoxide. More specifically, the phosphate is sodium phosphate. More specifically, the acetate is sodium acetate. More specifically, the citrate is sodium citrate.
[0076] Specifically, the medium of the lipid solution is ethanol, isopropanol or dimethyl sulfoxide; wherein the lipid nanoparticles are further purified by dialysis or ultrafiltration.
[0077] Specifically, the pharmaceutical composition is a lipid nanoparticle, and the average size of the lipid nanoparticle is 20nm to 1000nm, preferably 40nm to 150nm, more preferably 50nm to 100nm, and more preferably 70nm to 100nm.
[0078] Specifically, the polydispersity index of the lipid nanoparticles is ≤0.5, further preferably ≤0.3, and more preferably ≤0.25.
[0079] Specifically, the lipid nanoparticles have a nucleic acid encapsulation ratio of at least 70%.
[0080] Specifically, the lipid nanoparticles generally also contain one or more pharmaceutically acceptable excipients (such as neutral buffered saline or phosphate buffered water), carbohydrates (such as glucose, mannitol, sucrose, trehalose, dextrose or dextran), mannitol, proteins, polypeptides or amino acids (such as glycine and lysine), antioxidants (vitamin E and butylated hydroxytoluene), antibacterial agents, chelating agents (such as EDTA and glutathione), adjuvants (such as aluminum hydroxide), suspending agents / thickening agents / preservatives that make the preparation isotonic with the recipient's blood, etc., or the composition of the present invention can be formulated into a lyophilizate.
[0081] On the other hand, the present invention also provides the polymer lipid compound or its pharmaceutically acceptable salt, ester, isomer, prodrug and solvate as described in the above technical solution, the composition described in the above technical solution, and the lipid nanoparticles described in the above technical solution for preparing drugs for preventing and / or treating diseases, and for preventing and / or treating diseases.
[0082] Specifically, in this method, the administration methods include but are not limited to intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intratumoral injection, ocular administration, ear administration, nasal administration, oral administration, anal administration, vaginal administration, etc.
[0083] Specifically, in this method, the subject can be any animal or its cells (in vitro or in situ) that are subjected to the method; more specifically, the subject includes mammals such as cows, horses, mules, donkeys, camels, pigs, sheep, dogs, foxes, rabbits, etc., poultry such as chickens, ducks, geese, pigeons, etc., fish, non-human primates, and humans.
[0084] Bile acid is a naturally occurring steroid molecule found in humans and mammals. It is synthesized in the liver from cholesterol. After ingestion, bile acid is actively secreted by hepatocytes and transported with bile into the gallbladder. From there, it enters the intestines to perform its digestive function. Bile acid enters the small intestine as a sodium salt, aiding in the digestion and absorption of lipids. Bile acid then returns to the liver via the portal vein at the terminal ileum, either through active absorption or passive transport. It is then processed and transformed within hepatocytes before being secreted back into the small intestine along with newly synthesized bile acids. This enterohepatic circulation (EHC) of bile acid occurs 4 to 12 times daily, with approximately 95% of bile acid being recycled. Disruption of the EHC of bile acid not only impairs lipid digestion and absorption but can also lead to the formation of cholesterol gallstones. Therefore, the greatest advantage of compound delivery vehicles designed based on bile acid is its high efficiency in enterohepatic circulation. By participating in this enterohepatic circulation of bile acid, the drug is enhanced in the liver and gallbladder. The structural formula of bile acid is shown below.
[0085] The three six-membered rings and one five-membered ring on the steroidal skeleton of the bile acid molecule are located in the same plane, with Ring A and Ring B connected in opposite directions, forming a cavity-like structure. The three methyl groups in the molecule are located on one side of the plane where the steroid rings lie, forming the hydrophobic portion of the molecule, while the three hydroxyl groups are located on the other side of the plane where the steroid rings lie, forming the hydrophilic portion of the molecule together with the carboxyl group at position C24.
[0086] The special structure of bile acid molecules determines that they are amphiphilic, acidic and alkaline, and easy to be chemically modified. Therefore, this patent uses bile acid as a building block to prepare polymers or oligomers. These functional molecules based on bile acid have good technical effects in drug delivery.
[0087] Bile acid drugs, including ursodeoxycholic acid, obeticholic acid, chenodeoxycholic acid, and tauroursodeoxycholic acid, have been available in China and the United States for many years. Ursodeoxycholic acid, for example, is used to treat cholesterol gallstones and bile reflux gastritis; obeticholic acid is used to treat primary biliary cirrhosis (PBC) in patients who do not adequately respond to or cannot tolerate ursodeoxycholic acid. Years of clinical application have demonstrated that bile acid compounds have a good safety profile. Furthermore, bile acid compounds possess amphiphilic, hydrophilic, and lipophilic properties, which can enhance the bioavailability of small molecule drugs through encapsulation or conjugation.
[0088] Bile acid compounds and cholesterol belong to the same class of steroid compounds, have similar structures, and have more sites that can be chemically modified. Structural modification of bile acid compounds to prepare new lipid components may replace the ionizable lipids, PEG lipids, and cholesterol in the original four-component LNP, achieving similar or better mRNA delivery effects. This patent research constructs lipid nanoparticle carriers based on bile acid analogs and explores their application in mRNA drug delivery. The LNP of the present invention can simplify the production process and reduce costs; at the same time, it can avoid the patent blockade of the four-component LNP, which is conducive to promoting the localization of nucleic acid drugs.
[0089] Because bile acid and its derivatives are all composed of a rigid steroid ring, consisting of three six-membered rings and one five-membered ring, and an aliphatic side chain. The side chain structure, steroid ring conformation, and the number and orientation of hydroxyl groups on the steroid ring vary depending on the source. The shared hydroxyl groups and carboxyl groups of bile acid and its derivatives, as well as the carboxyl groups of the aliphatic side chains, are both excellent sites for chemical modification. Therefore, we believe that bile acid and its derivatives can achieve the desired effect through common modifications.
[0090] GALA peptide is a targeting peptide composed of 30 amino acids with the sequence: WEAALAEALAEALAEHLAEALAEALEALAA; GALA peptide is an artificial sequence designed based on the fusion peptide on the viral envelope. It not only has the function of promoting phospholipid membrane fusion, but also has obvious acid sensitivity, which can promote lysosomal escape; it can serve as a pH-dependent endosomal escape inducer and a ligand targeting pulmonary endothelial cells. In this study, GALA-modified PEG lipids were used to replace traditional PEG lipids for the preparation of LNPs to achieve better targeted expression of mRNA.
[0091] Fibroblast activation protein (FAP) is a type II transmembrane serine protease belonging to the prolyl oligopeptidase family. It is highly expressed in many epithelial tumor-associated fibroblasts, such as those in liver cancer, colorectal cancer, pancreatic cancer, and ovarian cancer. It is also highly expressed in lesions characterized by interstitial tissue activation, such as infectious, inflammatory, and fibrotic diseases, and in healing wounds. However, it is absent or expressed at low levels in normal tissues and benign tumor stroma. The FAP inhibitor (FAPI) has a high affinity and specificity for FAP on the surface of fibroblasts (CAFs). Leveraging this high affinity and specificity for FAP, FAPI-modified PEG lipids can replace traditional PEG lipids in the preparation of LNPs to achieve better targeted mRNA expression.
[0092] The technical solution of the present invention provides a new class of lipid compounds for delivering therapeutic or preventive drugs, namely lipids based on bile acid or its derivatives. The technical solution of the present invention is different from the existing patented technical solutions of foreign pharmaceutical companies. It enriches the types of lipid compounds and provides more options for the delivery of nucleic acid drugs, gene vaccines, peptides, proteins, antibodies and small molecule drugs, etc., and can be significantly different from the technical routes of foreign companies such as Pfizer and Moderna. BRIEF DESCRIPTION OF THE DRAWINGS
[0093] Figure 1 is a hydrogen nuclear magnetic resonance spectrum of an ursodeoxycholic acid derivative (Compound 1).
[0094] Figure 2 is a hydrogen nuclear magnetic resonance spectrum of an ursodeoxycholic acid derivative (Compound 2).
[0095] Figure 3 is a hydrogen nuclear magnetic resonance spectrum of an ursodeoxycholic acid derivative (Compound 3).
[0096] Figure 4 is a hydrogen nuclear magnetic resonance spectrum of a lithocholic acid derivative (Compound 11).
[0097] Figure 5 is a hydrogen nuclear magnetic resonance spectrum of a lithocholic acid derivative (Compound 14).
[0098] FIG6 is a graph showing the expression of fluorescent protein in mice after intravenous injection.
[0099] FIG7 is a diagram showing the expression of fluorescent protein in mice after intramuscular injection.
[0100] FIG8 is a hydrogen nuclear magnetic resonance spectrum of compound P001.
[0101] FIG9 is a hydrogen nuclear magnetic resonance spectrum of compound P002.
[0102] FIG10 is a hydrogen nuclear magnetic resonance spectrum of compound P003.
[0103] Figure 11 is a diagram of fluorescent protein expression in mice. DETAILED DESCRIPTION
[0104] The polymer lipid compound described in this patent is one or more compounds selected from the following structures;
[0105] ① Ursodeoxycholic acid derivative lipids:
[0106] ② Lithocholic acid derivative lipids:
[0107] The present invention is further described below with reference to the following examples, but the present invention is not limited to the following examples. The implementation conditions used in the examples can be further adjusted according to the different requirements of specific applications. The implementation conditions not specified are conventional conditions in the industry. The technical features involved in the various embodiments of the present invention may be combined with each other as long as they do not conflict with each other.
[0108] Example
[0109] The following abbreviations are used herein: BrBn: benzyl bromide TEA: triethylamine HATU: N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate DIPEA: N,N-diisopropylethylamine HBTU: benzotriazole-N,N,N′,N′-tetramethyluronium hexafluorophosphate mPEG-2000-NH2: methoxypolyethylene glycol amine Py: pyridine MeCN: acetonitrile DMF: N,N-dimethylformamide DCM: dichloromethane MeOH: methanol TLC: thin layer chromatography
[0110] The present invention is further described in detail below with reference to specific embodiments and Tables 1-4 so that those skilled in the art can better understand the present invention and thus more clearly define the protection scope of the present invention.
[0111] Example 1: Synthesis of ursodeoxycholic acid derivative (Compound 1):
[0112] Synthesis of Intermediate 1-1: Ursodeoxycholic acid (10 g, 25.5 mmol), acetonitrile (100 mL), benzyl bromide (6.5 g, 38.2 mmol), and potassium carbonate (6.9 g, 51 mmol) were added to a reaction flask in sequence. The temperature was then raised to 50°C and the reaction was allowed to proceed overnight. TLC indicated the reaction was complete. The reaction mixture was diluted with water and extracted with ethyl acetate. The organic phase was dried, concentrated, and chromatographed on a silica gel column using DCM / CH3OH (10:1) as the eluent to afford 1-1 (9.96 g, 81%) as a white solid. 1 HNMR (400MHz, CDCl3) δ7.32-7.36(m,5H),5.08-5.15(m,2H),3.55-3.62(m,2H),0.94(s,3H,CH3),0.91(d,3H,CH3),0.65(s,3H,CH3). HPLC: 98.41%.
[0113] Synthesis of Intermediate 1-2: Dissolve 2-hexyldecanoic acid (2.4 g, 9.5 mmol) in DCM (50 mL), add 1 drop of DMF, then slowly add oxalyl chloride (4.7 g, 37.2 mmol) dropwise. Stir and react for 1 hour. The reaction mixture is concentrated to obtain the crude product. The crude acyl chloride is dissolved in DCM and added dropwise to a reaction flask containing compound 1-1 (1.5 g, 3.1 mmol), TEA (5.3 mL, 37.2 mmol), and DCM (20 mL). Stir and react at room temperature overnight. After TLC, add an appropriate amount of water and extract with dichloromethane. The organic phase is dried, concentrated, and eluted with silica gel column chromatography using DCM / CH3OH (30:1) to obtain 1-2 (1.7 g, 76.8%) as a pale yellow oil. 1 HNMR(400MHz, CDCl3)δ7.37-7.31(m,5H),5.14-5.08(m,2H),4.75-4.67(m,1H),2.45-2.36(m,1H),2.32-2.20(m,2 H),2.02-1.97(m,1H),1.91-1.76(m,5H),0.96(s,3H,CH3),0.92(d,3H,CH3),0.89-0.86(m,6H),0.66(s,3H,CH3).
[0114] Synthesis of Intermediate 1-3: Compound 1-2 (400 mg, 0.42 mmol) and Pd / C (40 mg) were dissolved in methanol (10 mL) and stirred overnight at room temperature under a hydrogen atmosphere. TLC was performed. After completion of the reaction, the reaction mixture was filtered through celite, and the mother liquor was concentrated to afford the crude product. Silica gel column chromatography, eluting with DCM / CH3OH (20:1), afforded 1-3 as a colorless oil (210 mg, 60%). 1 HNMR(400MHz, CDCl3)δ4.73-4.68(m,1H),3.62-3.56(m,1H),2.44-2.36(m,1H),2 .30-2.22(m,2H),0.96-0.93(m,6H,CH3×2),0.89-0.86(m,6H),0.68(s,3H,CH3).
[0115] Synthesis of Compound 1: Compound 1-3 (200 mg, 0.32 mmol), mPEG-2000-NH2 (760 mg, 0.38 mmol), HATU (180 mg, 0.48 mmol), and TEA (96 mg, 0.95 mmol) were dissolved in DMF (4 mL) and stirred at room temperature overnight. After TLC, the reaction mixture was concentrated to obtain the crude product. Silica gel column chromatography with DCM / CH3OH (15:1) as the eluent afforded 1 (320 mg, 38%) as an off-white solid. 1 H NMR (400 MHz, CDCl3,) δ 6.23-6.18 (m, 1H, NH), 4.74-4.66 (m, 1H), 3.82-3.43 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.30-2.20 (m, 2H), 0.95 (s, 3H, CH3), 0.94-0.92 (m, 3H, CH3), 0.89-0.85 (m, 6H, CH3×2), 0.67 (s, 3H, CH3). HPLC: 97.7%. The hydrogen nuclear magnetic resonance spectrum of compound 1 is shown in Figure 1 of the accompanying drawings.
[0116] Example 2: Synthesis of ursodeoxycholic acid derivative (Compound 2):
[0117] Ursodeoxycholic acid (200 mg, 0.51 mmol) was dissolved in DMF (10 mL). HATU (193.71 mg, 0.51 mmol), DIPEA (132 mg, 1.02 mmol), and mPEG-2000-NH2 (1.0 g, 0.51 mmol) were added sequentially. The mixture was stirred at room temperature overnight. After TLC, the solvent was removed under reduced pressure to obtain the crude product. Silica gel column chromatography with DCM / CH3OH (10:1) as the eluent afforded Compound 2 (510 mg, 43%) as an off-white solid. 1 H NMR (400 MHz, CDCl3) δ 6.26 (s, 1H), 3.82-3.44 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.27-2.20 (m, 2H), 0.94-0.92 (m, 6H, CH3×2), 0.67 (s, 3H, CH3). HPLC: 94.93%. The H NMR spectrum of Compound 2 is shown in Figure 2 of the accompanying drawings.
[0118] Example 3: Synthesis of ursodeoxycholic acid derivative (Compound 3):
[0119] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by tetradecanoic acid. Off-white solid, yield 45%. 1 H NMR (400 MHz, CDCl3,) δ 6.31 (s, 1H), 4.81-4.74 (m, 1H, C7), 4.71-4.63 (m, 1H, C3), 3.82-3.45 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.26-2.18 (m, 6H), 0.96 (s, 3H, CH3), 0.92-0.90 (m, 3H, CH3), 0.89-0.85 (m, 6H, CH3×2), 0.67 (s, 3H, CH3). HPLC: 93.27%. The H NMR spectrum of compound 3 is shown in Figure 3 of the accompanying drawings.
[0120] Example 4: Synthesis of ursodeoxycholic acid derivative (Compound 4):
[0121] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by stearic acid. Off-white solid, yield 42%. 1HNMR(400MHz,CDCl3,)δ6.19(m,1H),4.81-4.72(m,1H,C7),4.71-4.62(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.37(s,3H,O -CH3), 2.26-2.18(m,6H), 0.96(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.86(m,6H,CH3×2), 0.67(s,3H,CH3). HPLC: 95.15%.
[0122] Example 5: Synthesis of ursodeoxycholic acid derivative (Compound 5):
[0123] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by dodecanoic acid. Off-white solid, yield 51%. 1 HNMR(400MHz,CDCl3,)δ6.11(m,1H),4.81-4.72(m,1H,C7),4.71-4.63(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O -CH3), 2.26-2.18(m,6H), 0.96(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.85(m,6H,CH3×2), 0.66(s,3H,CH3). HPLC: 96.54%.
[0124] Example 6: Synthesis of ursodeoxycholic acid derivative (Compound 6):
[0125] The synthesis method refers to the synthesis of compound 1, except that the feed ratio of 2-hexyldecanoic acid is increased to 5.0 times. Off-white solid, yield 46%. 1 HNMR(400MHz,CDCl3)δ6.25(m,1H),4.81-4.75(m,1H,C7),4.71-4.65(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O- CH3), 2.26-2.19(m,4H), 0.97(s,3H,CH3), 0.92-0.90(m,3H,CH3), 0.89-0.85(m,12H,CH3×4), 0.68(s,3H,CH3). HPLC: 91.09%.
[0126] Example 7: Synthesis of ursodeoxycholic acid derivative (Compound 7):
[0127] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoic acid is replaced by acetyl chloride. Off-white solid, yield 57%. 1 HNMR(400MHz,CDCl3,)δ6.08-6.05(m,1H),4.78-4.71(m,1H,C7),4.69-4.61(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H ,O-CH3),2.26-2.18(m,4H),2.01(s,3H),1.97(s,3H),0.96(s,3H,CH3),0.91-0.90(m,3H,CH3),0.66(s,3H,CH3).HPLC: 97.19%.
[0128] Example 8: Synthesis of ursodeoxycholic acid derivative (Compound 8):
[0129] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by hexanoyl chloride. Off-white solid, yield 49%. 1 HNMR(400MHz, CDCl3)δ6.11-6.08(m,1H,NH),4.80-4.73(m,1H,C7),4.70-4.61(m,1H,C 3),3.81-3.79(m,1H),3.64-3.63(m,174H,PEG-chain),3.55-3.52(m,5H),3.46-3.41( m,3H),3.36(s,3H,O-CH3),2.25-2.17(m,6H),2.06-1.96(m,2H),1.82-1.24(m,38H),1 .15-1.00(m,3H),0.95(s,3H,CH3), 0.91-0.86(m,9H),0.66(s,3H,CH3). HPLC: 93.65%.
[0130] Example 9: Synthesis of ursodeoxycholic acid derivative (Compound 9):
[0131] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by octanoyl chloride. Off-white solid, yield 54%. 1HNMR (400MHz, CDCl3) δ6.11-6.08(s,1H),4.80-4.73(m,1H,C7),4.70-4.61(m,1H,C3),3.81-3.41(m,O-CH2-CH2-O),3.36(s, 3H,O-CH3), 2.25-2.17(m,6H), 2.06-1.96(m,2H), 0.95(s,3H,CH3), 0.91-0.86(m,9H,CH3×3), 0.66(s,3H,CH3). HPLC: 94.13%.
[0132] Example 10: Synthesis of ursodeoxycholic acid derivative (Compound 10):
[0133] The synthesis method refers to the synthesis of compound 1, except that 2-hexyldecanoyl chloride is replaced by decanoyl chloride. Off-white waxy solid, yield 56%. 1 HNMR(400MHz, CDCl3)δ6.11-6.08(s,1H),4.80-4.73(m,1H),4.62-4.70(m,1H),3.81-3.40(m,O-CH2-CH2-O),3.36(s,3H,O-CH3),2 .25-2.17(m,1H),2.08-2.00(m,2H),1.99-1.96(m,1H),0.95(s,3H,CH3),0.91-0.84(m,9H,CH3×3),0.65(s,3H,CH3). HPLC: 96.65%.
[0134] Example 11. Synthesis of lithocholic acid derivatives (Compound 11):
[0135] The synthesis method refers to the synthesis of compound 2, except that ursodeoxycholic acid is replaced by lithocholic acid. Off-white solid, yield 62.9%. 1 H NMR (400 MHz, CDCl3) δ 6.12 (s, 1H), 3.82-3.42 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.27-2.19 (m, 1H), 2.10-2.02 (m, 2H), 1.96-1.93 (m, 1H), 0.91-0.90 (m, 6H, CH3×2), 0.63 (s, 3H, CH3). HPLC: 97.85%. The H NMR spectrum of compound 11 is shown in Figure 4 of the accompanying drawings.
[0136] Example 12. Synthesis of lithocholic acid derivative (Compound 12):
[0137] Synthesis of Intermediate 12-2: Compound 12-1 (10 g, 2.66 mmol) and acetonitrile (200 mL) were added sequentially to a reaction flask. Benzyl bromide (5.9 g, 3.45 mmol) and potassium carbonate (5.5 g, 3.98 mmol) were added with stirring. The reaction mixture was warmed to 50°C and allowed to react overnight. TLC indicated completion of the reaction. The reaction mixture was filtered, the filtrate concentrated to dryness, and purified by silica gel column chromatography using DCM / CH3OH (20:1) as the eluent to afford 12-2 (10 g, 80%) as an off-white solid. 1 HNMR (400MHz, CDCl3) δ7.37-7.31(m,5H,ArH),5.14-5.08(m,2H,O-CH2-Ph),3.66-3.58(m,1H,C3),2.44-2. 36(m,1H),2.31-2.23(m,1H),1.96-1.92(m,1H),0.91-0.89(m,6H,CH3×2),0.62(s,3H,CH3). HPLC: 98.41%.
[0138] Synthesis of Intermediate 12-4: Compound 12-2 (470 mg, 1.0 mmol) and pyridine (8 mL) were added sequentially to a reaction flask, followed by the slow dropwise addition of the acid chloride 12-3 (490 mg, 3.00 mmol). After complete addition, the reaction was stirred overnight. TLC indicated completion of the reaction. The reaction mixture was quenched with water and extracted with dichloromethane. The organic phase was dried and concentrated. Silica gel column chromatography with DCM / CH3OH (10:1) afforded 12-4 as a pale yellow oil (506 mg, 85.1%). 1 HNMR(400MHz, CDCl3)δ7.39-7.31(m,5H,ArH),5.14-5.08(m,2H,O-CH2-Ph),4.77-4.69(m,1H,C3),2.44-2.36(m,1H ), 2.31-2.23(m,1H),1.97-1.93(m,1H),0.92(s,3H,CH3)0.92-0.88(m,6H,CH3×2),0.62(s,3H,CH3). HPLC: 96.85%.
[0139] Synthesis of Intermediate 12-5: To a reaction flask, add Intermediate 12-4 (417 mg, 0.70 mmol), MeOH (6 mL), and Pd / C (150 mg, 35 wt%). After replacing the atmosphere with hydrogen three times, the reaction was stirred at room temperature overnight. TLC indicated complete reaction. The reaction mixture was filtered through Celite, and the filtrate was concentrated and chromatographed on a silica gel column using DCM / CH3OH (10:1) as the eluent to afford 12-5 (250 mg, 70%) as a white solid. 1HNMR (400MHz, CDCl3) δ4.77-4.69(m,1H,C3),2.44-2.36(m,1H),2.30-2.22(m,1H),1.98-1. 94(m,1H),0.93-0.91(s,6H,CH3×2)0.89-0.86(m,3H,CH3),0.64(s,3H,CH3). HPLC: 98.08%.
[0140] Synthesis of Compound 12: Intermediate 12-5 (101 mg, 0.20 mmol) and DMF (2 mL) were added to a reaction flask. After stirring to dissolve, HBTU (100 mg, 0.26 mmol) and DIPEA (80 mg, 0.60 mmol) were added and stirred for 5 minutes. mPEG-2000-NH2 (485 mg, 0.24 mmol) was added and stirred at room temperature overnight. TLC indicated completion of the reaction. The reaction solution was concentrated and chromatographed on a silica gel column. Elution with DCM / CH3OH (10:1) afforded 12 (433 mg, 86.3%) as an off-white solid. 1 HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.67(m,1H,C3),3.81-3.41(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.09-1.99(m,2H),1.96-1.93(m,1H),0.91-0.85(m,9H,CH3×3),0.62(s,3H,CH3). HPLC: 97.10%.
[0141] Example 13. Synthesis of lithocholic acid derivatives (Compound 13):
[0142] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by decanoyl chloride. Off-white solid, yield 73.2%. 1 HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.69(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.09-2.03(m,2H),1.97-1.94(m,1H),0.92-0.85(m,9H,CH3×3),0.63(s,3H,CH3). HPLC: 98.85%.
[0143] Example 14. Synthesis of lithocholic acid derivative (Compound 14):
[0144] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced with dodecanoyl chloride. Off-white solid, yield 78.6%. 1H NMR (400 MHz, CDCl3) δ 6.19-6.14 (s, 1H), 4.75-4.68 (m, 1H, C3), 3.82-3.42 (m, O-CH2-CH2-O), 3.37 (s, 3H, O-CH3), 2.27-2.21 (m, 3H), 2.09-1.99 (m, 2H), 1.97-1.94 (m, 1H), 0.92-0.85 (m, 9H, CH3×3), 0.63 (s, 3H, CH3). HPLC: 98.56%. The H NMR spectrum of compound 14 is shown in Figure 5 of the accompanying drawings.
[0145] Example 15: Synthesis of lithocholic acid derivative (Compound 15):
[0146] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by tetradecanoyl chloride. Off-white solid, yield 67.8%. 1 HNMR(400MHz,CDCl3,)δ6.19-6.14(s,1H),4.75-4.67(m,1H,C3),3.82-3.41(m,O-CH2-CH2-O),3.37(s,3H,O-CH3), 2.27-2.21(m,3H),2.07-2.02(m,2H),1.96-1.93(m,1H),0.91-0.85(m,9H,CH3×3),0.62(s,3H,CH3). HPLC: 95.31%.
[0147] Example 16: Synthesis of lithocholic acid derivative (Compound 16):
[0148] The synthesis method refers to the synthesis of compound 12, except that octanoyl chloride is replaced by 2-hexyldecanoyl chloride. Off-white solid, yield 55%. 1 HNMR(400MHz,CDCl3,)δ6.16(s,1H),4.81-4.73(m,1H,C3),3.82-3.42(m,O-CH2-CH2-O),3.38(s,3H,O-CH3),2. 24-2.20(m,3H),2.01-1.94(m,2H),0.92(s,3H,CH3),0.91-0.85(m,9H,CH3×3),0.63(s,3H,CH3). HPLC: 94.97%.
[0149] Example 17: Preparation of lipid nanoparticles
[0150] According to the classic formula of SM102: DSPC: cholesterol: PEG lipids at a molar ratio of 50:38.5:10:1.5, DMG-PEG2000 was used as a yang ginseng and then dissolved in ethanol. Luciferase mRNA (encoding luciferase mRNA) was diluted in 20mM citrate buffer (pH=4) to obtain an mRNA solution. The ethanol lipid solution and mRNA solution were mixed in a microfluidic device at a volume ratio of 1:3. Liposomes were prepared with a total lipid to mRNA weight ratio of 20:1. Ethanol was removed by dialysis or tangential flow filtration. The final lipid nanoparticles were stored in PBS solution and filtered through a 0.22μm sterile filter to obtain the final lipid nanoparticles.
[0151] Example 18: Characterization of lipid nanoparticles
[0152] Particle size (size), polydispersity index (PDI), and zeta potential (Zeta P) were determined by dynamic light scattering using a Malvern Zetasizer NanoZS. The encapsulation efficiency of the lipid nanoparticles was determined using the Quant-it Ribogreen RNA Quantification Kit (Thermo Fisher Scientific, UK). As shown in Table 1, the lipid nanoparticles were mostly around 100 nm in size, with a potential of approximately 0 mV, a polydispersity index of approximately 0.1, and an encapsulation efficiency of approximately 90%.
[0153] Table 1: Characterization of lipid nanoparticles
[0154] Example 19: Preliminary in vitro cell transfection experiment of lipid nanoparticles
[0155] 293T cells were planted in 96-well cell culture plates at a density of 3X10^4 / well and grown to 24h to adhere to the wall. Prepared according to the preparation method in Example 17, the compounds in Table 2 were prepared into lipid nanoparticles according to the method in Example 17 and added to the cells. After 24h of culture, a color developing solution was added and the luminescence value of each well was detected by a microplate reader. Table 3 shows that lipid nanoparticles can carry mRNA for transfection into 293T cells and express the target fluorescent protein. A and B represent the results of the comparative evaluation of the compound and the commercial SM102 lipid formula. The luminous flux was normalized after the multiple ratio. As shown in Table 2, the luminous flux of compound 1, compound 12, compound 13, and compound 14 reached the same level as SM102-LNP, indicating that the newly synthesized PEG lipid can replace DMG-PEG2000.
[0156] Note: A and B represent the normalized results of the ratio of the luminescence flux of the lipid compound to that of SM102-LNP, respectively. The ratio range is as follows:
[0157] A: ≥0.5
[0158] B: ≥0.1 and <0.5
[0159] Table 2: In vitro cell transfection evaluation results of lipid nanoparticles
[0160] Example 20: Fluorescent protein expression experiment of lipid nanoparticles injected into mice.
[0161] Female SPF-grade BALB / c mice aged 6-8 weeks (n=3) were housed in an SPF-grade animal room at a temperature of 20-26°C and a humidity of 40-70%, with adequate feed and water. Lipid nanoparticles were prepared using the preparation method of the formulation in Example 17 at a dose of 100 μL (0.05 μg / μL) by intramuscular injection and intravenous administration, respectively. A control group used SM102-LNP for in vivo effect comparison. Six hours after administration, 200 μL of 15 mg / ml D-luciferin potassium salt was intraperitoneally injected. In vivo imaging was performed 5 minutes after the D-luciferin potassium salt injection. All groups were injected with D-luciferin potassium salt again after the completion of in vivo imaging, and organ imaging was performed 5 minutes later. A and B represent the normalized fluorescence expression values of the compounds compared to the commercial SM102-LNP. As shown in Table 3, compounds 9, 10, 12, 13, 14, 15, and 16 exceeded the SM102-LNP level at the injection site after intramuscular injection, demonstrating that our synthetic lipids can effectively replace DMG-PEG2000 in mRNA delivery and achieve high local expression of the target gene protein. Table 4 compares the results after intravenous injection with the commercial SM102-LNP. As shown in Table 4, compounds 10, 12, 13, 14, and 15 achieved SM102-LNP-level fluorescence in the abdomen, demonstrating that PEG-based lipid compounds can efficiently express the target gene protein via intravenous injection. Figures 6 and 7 show fluorescent protein expression in mice.
[0162] Note: A and B represent the normalized results of the luminescence values of the compound and SM102-LNP, respectively. The ratio range is as follows:
[0163] A: ≥0.5
[0164] B: ≥0.1 and <0.5
[0165] Table 3: Ratio and score of local fluorescence expression in mice muscles after intramuscular injection
[0166] Table 4: Fluorescence expression ratio and score in the abdomen of mice after intravenous injection
[0167] Example 21: The synthetic route of P001 is as follows:
[0168] Synthesis of Intermediate 1-2: Dissolve Intermediate 1-1 (400 mg, 0.83 mmol) in pyridine (4 mL) under nitrogen atmosphere and cool to 0-2°C in an ice bath. Add decanoyl chloride (948 mg, 4.97 mmol) dropwise. After addition, warm to room temperature and stir overnight. Follow with TLC. After completion of the reaction, add ethyl acetate (20 mL). Wash twice with hydrochloric acid (1 M, 20 mL). The organic layer is then washed once with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the solvent concentrated to obtain the crude product. Purify by silica gel column chromatography with PE / EA (9:1) as the eluent to afford a colorless oil (570 mg, 87%).
[0169] 1 HNMR(400MHz, CDCl3,)δ7.39-7.31(m,5H),5.14-5.07(dd,J1=12Hz,J2=16Hz,2H),4.81-4.74(m,1H),4.71-4.66(m,1H) ,2.43-2.35(m,1H),2.30-2.16(m,5H),2.00-1.95(m,1H),0.96(s,3H,CH3),0.91-0.86(m,9H,CH3×3),0.65(s,3H,CH3).
[0170] Synthesis of Intermediate 1-3: Intermediate 1-2 (570 mg, 0.72 mmol) was dissolved in MeOH (8 mL) and THF (8 mL). 10% Pd / C (50 mg, 30% wt) was added, and the atmosphere was replaced with hydrogen three times. The reaction was stirred at 30°C for 4 h. TLC was used for monitoring. After completion of the reaction, the mixture was filtered through celite, and the filter cake was washed twice with DCM. The organic layers were combined and the solvent was concentrated to obtain the crude product. Silica gel column chromatography with DCM / MeOH (30:1) as the eluent gave a colorless oil (285 mg, 56%).
[0171] 1HNMR(400MHz, CDCl3,)δ4.82-4.75(m,1H),4.70-4.65(m,1H),2.43-2.35(m,1H),2.29-2.17(m,6H) ,2.04-1.97(m,2H),0.97(s,3H),0.93(d,J=4Hz,3H),0.89-0.86(m,6H),0.68(s,3H).HPLC:99.6%.
[0172] Synthesis of Compound P001: Intermediate 1-3 (200 mg, 0.28 mmol) was dissolved in DCM / MeCN (8 mL) at room temperature. Methyl-PEG2000 (685 mg, 0.34 mmol), TCFH (104 mg, 0.37 mmol), and NMI (58 mg, 0.71 mmol) were added sequentially under nitrogen and stirred at room temperature overnight. TLC was performed. After completion of the reaction, MeOH (2 mL) was added and stirred at room temperature for 10 min. The reaction mixture was directly concentrated to obtain the crude product. The product was purified by silica gel column chromatography using DCM / MeOH (25:1) as the eluent, yielding a white waxy solid (140 mg, 18%).
[0173] 1 HNMR (400MHz, CDCl3) δ4.80-4.74(m,1H),4.70-4.62(m,1H),4.20(t,J=4Hz,2H),3.80(d,J=4Hz,1H),3.71-3.63(m,198H,PEG-chain),3.54-3.52(m,3H ),3.46-3.44(m,1H),3.36(s,3H),2.39-2.32(m,1H),2.25-2.17(m,5H),2. 02-1.96 (m, 4H), 0.96 (s, 3H), 0.90-0.79 (m, 12H), 0.66 (s, 3H). HPLC: 97.8%.
[0174] The H NMR spectrum of compound P001 is shown in Figure 8 of the accompanying drawings.
[0175] Example 22: The synthetic route of compound P002 is as follows:
[0176] Synthesis of Intermediate 12-2: Dissolve Intermediate 12-1 (2.0 g, 5.31 mmol) in ACN (40 mL) at room temperature. Add Intermediate benzyl bromide (1.82 g, 10.62 mmol) and KCO (2.94 g, 21.24 mmol) sequentially. Stir and react at 60°C overnight under nitrogen. TLC analysis is performed. After completion of the reaction, add an appropriate amount of water and extract twice with EA. The organic layers are combined, dried over anhydrous sodium sulfate, filtered, and the solvent concentrated to obtain the crude product. Silica gel column chromatography with PE / EA (1:1) as the eluent afforded a white solid (1.78 g, 72%). HPLC purity: 97.33%.
[0177] Synthesis of Intermediate 12-4: Myristic acid (293.60 mg, 1.29 mmol) was dissolved in a 2:1 mixture of ACN (10 mL) and DCM (5 mL) at room temperature. TCFH (601.19 mg, 2.14 mmol) and NMI (307.87 mg, 3.75 mmol) were added sequentially. After stirring for 15 minutes, 12-2 (500.0 mg, 1.07 mmol) was added and the mixture was stirred at room temperature for 3 hours. TLC was used for analysis. After completion of the reaction, an appropriate amount of water was added and the mixture was extracted twice with DCM. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography using PE / DCM (1:1) as the eluent to afford a white solid (500.0 mg, 68.96%).
[0178] 1 H NMR(400MHz,Chloroform-d)δ7.40–7.30(m,4H),5.11(d,J=2.6Hz,2H),4.73(t,J=5.1Hz,1H),2.38(dd,J=10.1,4.9Hz,1H),2.28(dt,J=1 2.5, 7.3Hz, 3H), 2.00–1.74 (m, 6H), 1.72–1.49 (m, 8H), 1.49–1.16 (m, 32H), 1.07 (m, 6H), 0.96–0.76 (m, 9H), 0.62 (s, 3H). HPLC purity: 96.89%.
[0179] Synthesis of Intermediate P002-1: Dissolve Intermediate 12-4 (400.0 mg, 0.590 mmol) in MeOH (5 mL), add 10% Pd / C (62.87 mg, 10% wt), replace the atmosphere with hydrogen three times, and stir at 30°C overnight. After TLC analysis, the filtrate was filtered and the filter cake washed twice with DCM. The organic layers were combined and the solvent was concentrated to obtain the crude product. Silica gel column chromatography, eluting with DCM / MeOH (20:1), afforded a white solid (301.0 mg, 86.99%). HPLC purity: 94.34%
[0180] Synthesis of Compound P002: Intermediate P002-1 (140 mg, 0.238 mmol) was dissolved in a 2:1 mixture of ACN (10 mL):DCM (5 mL). TCFH (133.85 mg, 0.477 mmol) and NMI (68.55 mg, 0.835 mmol) were added sequentially. After stirring for 15 minutes, PEG2000 (610.98 mg, 0.310 mmol) was added and the mixture was stirred at room temperature for 3 hours. TLC was performed. After completion of the reaction, an appropriate amount of water was added and the mixture was extracted twice with DCM. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and the solvent was concentrated to obtain the crude product. Silica gel column chromatography with DCM / MeOH (20:1) as the eluent gave a white solid (338.0 mg, 55.86%).
[0181] 1 H NMR(400MHz,Chloroform-d)δ4.73(s,0H),4.22(t,J=4Hz,2H),3.85–3.80(m,1H),3 .64(s,179H),3.57–3.53(m,2H),3.47(m,1H),3.38(s,3H),2.26(t,J=7.6Hz,3H),1 .96(d,J=11.7Hz,1H),1.77(s,13H),1.71–1.48(m,6H),1.41(d,J=12.4Hz,8H),1.34–1.16(m,31H),1.17–0.97(m,7H),0.97–0.74(m,11H),0.64(s,3H).HPLC purity: 98.12%
[0182] The H NMR spectrum of compound P002 is shown in Figure 9 of the accompanying drawings.
[0183] Example 23. The synthetic route of lithocholic acid derivative (Compound P003) is as follows:
[0184] Synthesis of Compound 12-2: To a single-necked flask, add lithocholic acid (10 g, 2.66 mmol) and suspend in ACN (200 mL). Stir and add benzyl bromide (5.9 g, 3.45 mmol), K2CO3 (5.5 g, 3.98 mmol), and KI (880 mg, 0.27 mmol). Stir and react at 70°C overnight. TLC indicates completion of the reaction. Filter the reaction mixture, and wash the filter cake with EA (50 mL). Concentrate the filtrate to dryness. Dissolve and dilute with EA (100 mL), then wash twice with water and saturated NaCl solution (100 mL). Dry, concentrate, and elute with silica gel column chromatography using DCM / MeOH (10:1) to obtain a white solid (5 g, 40%). HPLC: 98%.
[0185] Synthesis of Compound P003-2: Compound 12-2 (500 mg, 1.07 mmol) was added to a single-necked flask and dissolved in DCM / ACN (10 mL / 10 mL). Stirring allowed to dissolve. Compound P003-1 (412 mg, 1.61 mmol), NMI (439 mg, 5.36 mmol), and finally TCFH (751 mg, 1.61 mmol) were added. The mixture was stirred at room temperature for 12 h. TLC indicated completion of the reaction. Post-treatment: The reaction mixture was quenched with water (3 mL) and concentrated to remove the solvent. The residue was dissolved in DCM (15 mL), washed three times with water and then with NaCl solution (15 mL), then dried and concentrated. Purification by silica gel column chromatography using PE / DCM (1:1) as the eluent afforded a colorless oil (690 mg, 91.4%). HPLC analysis indicated 96.4%.
[0186] Synthesis of Compound P003-3: Compound P003-2 (680 mg, 0.96 mmol) was dissolved in MeOH (15 mL) in a single-necked flask. Pd / C (238 mg, 35% MT) was then added. The atmosphere was replaced with hydrogen three times. The reaction was stirred at 35°C under a hydrogen atmosphere for 12 h. TLC indicated complete reaction of the starting material. The reaction mixture was filtered through Celite. The filter cake was washed with DCM (10 mL). The filtrate was concentrated and the sample was subjected to silica gel column chromatography. Elution with DCM / MeOH (20:1) afforded a colorless oil (569 mg, 95.9%). HPLC analysis revealed 99.15%.
[0187] Synthesis of Compound P003: Compound P003-3 (150 mg, 0.24 mmol) was added to a single-necked flask and dissolved in DCM / ACN (2 mL / 2 mL). Stirring was performed until fully dissolved. Compound P003-4 (585 mg, 0.29 mmol), NMI (100 mg, 1.22 mmol), and TCFH (171 mg, 0.61 mmol) were then added and stirred for 12 h. TLC indicated completion of the reaction. The reaction mixture was quenched with water (3 mL) and concentrated to remove the solvent. The residue was dissolved in DCM (5 mL), washed three times with water and then with aqueous NaCl (5 mL), then dried and concentrated. Elution with DCM / MeOH (10:1) afforded an off-white waxy solid (400 mg, 62.7%). 1 H NMR (400MHz, Chloroform-d) δ4.76 (m, 1H), 4.22 (t, J = 4Hz, 2H), 3.75 (b, 1H), 3.57-3.72 (m, 212H), 3.55 (m, 2H), 3.47 (m, 1H ), 3.38(s,3H), 2.45–2.14(m,3H), 2.06–1.70(m,16H), 1.69–0.98(m,50H), 0.98–0.54(m,13H), 0.64(s,3H). HPLC: 95.86%.
[0188] The H NMR spectrum of compound P003 is shown in Figure 10 of the accompanying drawings.
[0189] Example 24: The synthetic route of LCA-PEG-GALA (P004) is as follows:
[0190] Synthesis of intermediate LCA-PEG2000: Compound P003-3 (85 mg, 0.138 mmol), Mal-PEG2000-NH2 (309 mg, 0.138 mmol), HATU (63 mg, 0.166 mmol), and DMAP (25 mg, 0.207 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 15 h. TLC confirmed the reaction was complete, and the reaction solution was concentrated to obtain the crude product. The crude product was purified by silica gel column chromatography using DCM / CH3OH (10:1) as the eluent and concentrated to afford the product as a white waxy solid (92 mg, 23.3%).
[0191] 1HNMR(400MHz,CDCl3)δ6.68(s,1.3H),6.39-6.32(m,1.6H),4.78-4.70(m,1.3H),3.81-3.63(m,158H,PE G-chain),3.56-3.53(m,2H),3.51-3.48(m,1H),3.47-3.44(m,3.3H),0.92-0.85(m,12H),0.63(s,3H).
[0192] Synthesis of the final product, LCA-PEG2000-GALA: Dissolve LCA-PEG2000 (20 mg, 0.007 mmol) and GALA (22 mg, 0.007 mmol) in DMF (1 mL) and stir at room temperature for 15 h. Reverse-phase HPLC (mobile phase A: 0.1% water, mobile phase B: acetonitrile, gradient elution: B:A = 60:40 to 95:5) was used, and the product was freeze-dried to afford a white solid (10 mg, 23.8%).
[0193] MALDI-TOF MS: M+H + + / -n*44=6119.444
[0194] The LCA-PEG2000-GALA compound was named P004
[0195] Example 25:
[0196] The synthetic route of LCA-PEG2000-FAPI (P005) is as follows:
[0197] The synthesis method of the intermediate FAPI refers to patent CN113582975A, and 1.3 g of an off-white foamy crude product is obtained, with MS: 451.2.
[0198] Synthesis of the intermediate Boc-PEG2000-FAPI: Dissolve FAPI (164 mg, 0.363 mmol), Boc-NH-PEG2000-COOH (782 mg, 0.363 mmol), HATU (165 mg, 0.436 mmol), and DIPEA (281 mg, 2.178 mmol) in DMF (3 mL) and stir at room temperature for 2 h. After TLC analysis, the reaction mixture was concentrated to yield the crude product. Silica gel column chromatography, eluting with DCM / CH3OH (10:1 + 0.5% NH3), afforded a pale yellow oil (670 mg, 71.3%).
[0199] 1HNMR(400MHz, CDCl3)δ8.78(d,J=4.0,0.5H),8.01(d,J=8.0,0.5H),7.74-7.73(m,0.5H),7.49(d,J=4.0,0.5H),7.37(dd,J1= 8.0, J2=4.0,0.5H),4.79-4.77(m,0.5H),4.41-4.26(m,1H),3.81-3.51(m,186H,PEG-chain),3.31-3.28(m,2H),1.43(s,9H).
[0200] Synthesis of intermediate PEG2000-FAPI: Boc-PEG2000-FAPI (400 mg, 0.155 mmol) and p-toluenesulfonic acid (104 mg, 0.618 mmol) were dissolved in acetonitrile (4 mL) and stirred at 65°C for 3 h. After completion of the reaction, the solvent was concentrated to afford the crude product. Silica gel column chromatography with DCM / CH3OH (10:1 + 0.5% NH3) as the eluent afforded a colorless oil (283 mg, 72.5%).
[0201] 1 HNMR (400MHz, CDCl3) δ8.78(d,J=4.0,1H),8.01(d,J=8.0,1H),7.71-7.69(m,2H),7.49(d,J=4.0,1H),7.37(dd,J1=8.0,J2 =4.0,1H),7.10(d,J=8.0,2H),4.80-4.77(m,1H),4.41-4.25(m,2H),3.83-3.61(m,222H,PEG-chain),3.19(d,J=4.0,2H).
[0202] Synthesis of the final product, LCA-PEG2000-FAPI: Dissolve PEG2000-FAPI (100 mg, 0.04 mmol), P003-3 (37 mg, 0.06 mmol), HATU (30 mg, 0.08 mmol), and DIPEA (10 mg, 0.08 mmol) in DMF (2 mL) and stir at room temperature for 15 h. After TLC analysis, the reaction mixture was concentrated to yield the crude product. Silica gel column chromatography, eluting with DCM / CH3OH (10:1 + 0.5% NH3), afforded a white waxy solid (65 mg, 52.8%).
[0203] 1HNMR(400MHz, CDCl3)δ8.78(d,J=8.0,1H),8.00(d,J=8.0,1H),7.71(br,1H),7.50(d,J=4.0 ,1H),7.37(dd,J1=8.0,J2=4.0,1H),7.15-7.13(m,1H),6.28(br,1H),4.78-4.74(m,1H),4.3 5(d,J=8.0,2H),4.26(s,2H),4.23-4.20(m,2H),3.81-3.53(m,199H,PEG-chain),3.45-3.4 2(m,4H),2.68-2.64(m,2H),2.58-2.54(m,4H),0.92(s,3H),0.90-0.82(m,9H),0.63(s,3H).
[0204] MALDI-TOF MS: M+Na + + / -n*44=3108.046
[0205] The LCA-PEG2000-FAPI compound was named P005
[0206] Example 26. Preparation of lipid nanoparticles
[0207] According to the classic formula of SM102: DSPC: cholesterol: PEG lipids at a molar ratio of 50:38.5:10:1.5, DMG-PEG2000 was used as a yang ginseng and then dissolved in ethanol. Luciferase mRNA (encoding luciferase mRNA) was diluted in 20mM citrate buffer (pH=4) to obtain an mRNA solution. The ethanol lipid solution and mRNA solution were mixed in a microfluidic device at a volume ratio of 1:3. Liposomes were prepared with a total lipid to mRNA weight ratio of 20:1. Ethanol was removed by dialysis or tangential flow filtration. The final lipid nanoparticles were stored in PBS solution and filtered through a 0.22μm sterile filter to obtain the final lipid nanoparticles.
[0208] Example 27. Characterization of lipid nanoparticles
[0209] Particle size (Size), polydispersity index (PDI), and zeta potential (Zeta P) were determined by dynamic light scattering using a Malvern Zetasizer NanoZS. The encapsulation efficiency of the lipid nanoparticles was determined using the Quant-it Ribogreen RNA Quantification Kit (Thermo Fisher Scientific, UK). As shown in Table 4, the lipid nanoparticles were mostly around 100 nm in size, with a polydispersity index ranging from approximately 0.1 and an encapsulation efficiency of 90%.
[0210] Table 4: Characterization of lipid nanoparticles
[0211] Example 28. Preliminary in vitro cell transfection experiment of lipid nanoparticles
[0212] 293T cells were planted in 96-well cell culture plates at a density of 3X10^4 / well and grown to 24h until adherence. Prepared according to the preparation method in Example 17, the compounds in Table 4 were prepared into lipid nanoparticles according to the method in Example 17 and added to the cells. After 24h of culture, a color developing solution was added and the luminescence value of each well was detected by a microplate reader. Table 5 shows that lipid nanoparticles can carry mRNA for transfection into 293T cells and express the target fluorescent protein. A and B represent the results of the comparative evaluation of the compound and the commercial SM102 lipid formulation. The luminous flux was normalized after the multiple ratio. As shown in Table 5, the luminous flux of compound P001, compound P002, compound P003, compound P004 and compound P005 reached the same level as SM102-LNP, indicating that the newly synthesized PEG lipid can replace DMG-PEG2000.
[0213] Note: A and B represent the normalized results of the ratio of the luminescence flux of the lipid compound to that of SM102-LNP, respectively. The ratio range is as follows:
[0214] A: ≥0.5
[0215] B: ≥0.1 and <0.5
[0216] Table 5: In vitro cell transfection evaluation results of lipid nanoparticles
[0217] Example 29. Fluorescent protein expression experiment of lipid nanoparticles injected into mice.
[0218] Female SPF-grade BALB / c mice aged 6-8 weeks (n=3) were housed in an SPF-grade animal room at a temperature of 20-26°C and a humidity of 40-70%, with adequate feed and water. Lipid nanoparticles were prepared using the preparation method of the formulation in Example 17 at a dose of 100 μL (0.05 μg / μL) by intramuscular injection and intravenous administration, respectively. A control group used SM102-LNP for in vivo effect comparison. Six hours after administration, 200 μL of 15 mg / ml D-luciferin potassium salt was intraperitoneally injected. In vivo imaging was performed 5 minutes after the D-luciferin potassium salt injection. All groups were injected with D-luciferin potassium salt again after the completion of in vivo imaging, and organ imaging was performed 5 minutes later. A and B represent the normalized results of the fluorescence expression values of the compounds compared to the commercial SM102-LNP. As shown in Table 6, compounds P001 and P002 exceeded the SM102-LNP level at the injection site after intramuscular injection, demonstrating that our synthetic lipids can effectively replace DMG-PEG2000 in mRNA delivery and achieve high local expression of the target gene protein. Table 7 compares the results after intravenous injection with the commercial SM102-LNP. As shown in Table 7, compounds P001 and P002 achieved SM102-LNP-level fluorescence in the abdomen, demonstrating that PEG-based lipid compounds can effectively express the target gene protein via intravenous injection. Figure 11 shows fluorescent protein expression in mice.
[0219] Note: A and B represent the normalized results of the luminescence values of the compound and SM102-LNP, respectively. The ratio range is as follows:
[0220] A: ≥0.5
[0221] B: ≥0.1 and <0.5
[0222] Table 6: Ratio and score of local fluorescence expression in mice muscles after intramuscular injection
[0223] Table 7: Fluorescence expression ratio and score in the abdomen of mice after intravenous injection
[0224] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as within the scope of protection of the present invention.
Claims
1. [Corrected 24.06.2024 in accordance with Rule 26] A polymer lipid compound, characterized in that The polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure:
2. The polymer lipid compound according to claim 1, characterized in that Wherein bile acid or its derivative is selected from cholic acid, obeticholic acid, ursodeoxycholic acid, ursolic acid, 3β-hydroxy-D5-cholenic acid, chenodeoxycholic acid, lithocholic acid, deoxycholic acid, taurocholic acid, 5β-cholic acid, dehydrocholic acid, hyocholic acid, glycochenodeoxycholic acid, tauroursodeoxycholic acid, tauroursodeoxycholic acid, glycocholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium tauroursodeoxycholate, sodium dehydrocholate, sodium cholate, sodium deoxyglycocholate, sodium taurodeoxycholate, sodium taurocholate, sodium tauroursodeoxycholate, sodium glycocholic acid sodium salt, taurocholic acid-3-sulfate disodium salt, sodium tauroursodeoxycholate and sodium taurolithocholate.
3. The polymer lipid compound according to claim 2, characterized in that The lipid compound is ursodeoxycholic acid or its derivatives, or lithocholic acid or its derivatives.
4. The polymer lipid compound according to claim 1, characterized in that The polymer molecular weight of the polymer lipid compound is 200-20000 Daltons; The two ends of the polymer in the polymer lipid compound are one or more of methoxy, amino, carboxyl, hydroxyl, sulfhydryl, sulfate, sulfonic acid and phosphate.
5. [Corrected 24.06.2024 according to Rule 26] The polymer lipid compound according to claim 1, characterized in that The linking molecules (L1, L2) in the polymer lipid compound are identical or different and are independently selected from: not present, or one or more of the following structures. In addition, the linking molecules (L1, L2) are connected to both ends via one or more of an ester group, an amide group, a carbamate group, a carbonate group, an ether group or a urea group; 6. A polymer-lipid compound conjugate, characterized in that: The conjugate is mainly composed of three parts: a therapeutic or preventive drug, a linker and a lipid compound as described in any one of claims 1-5. The therapeutic or preventive drugs include nucleic acids, proteins, polypeptides, antibodies, carbohydrates, small molecule compounds, etc.
7. The polymer-lipid compound conjugate according to claim 6, characterized in that: The nucleic acid of the therapeutic or preventive drug includes DNA and RNA, wherein the DNA may be non-coding DNA or coding DNA, and the RNA may be selected from one or more of ASO, mRNA, siRNA, and micRNA.
8. A composition of a polymer lipid compound, characterized in that: The composition comprises a therapeutic or preventive agent and a carrier for delivering the therapeutic or preventive agent, wherein the carrier comprises one or more of the polymer lipid compounds or conjugates thereof as described in claims 1 to 7.
9. The composition according to claim 8, characterized in that The therapeutic or preventive agent includes one or more of nucleic acid molecules, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs; The mass ratio of the carrier to the therapeutic or preventive agent is 1:1 to 100:
1.
10. The composition according to claim 8, characterized in that The composition is lipid nanoparticles, and the average size of the lipid nanoparticles is 20nm to 1000nm.
11. The composition according to claim 8, characterized in that The carrier comprises at least two different lipid components, wherein at least one of the lipids is a lipid based on bile acid or a derivative thereof.
12. The composition according to claim 8 or 11, characterized in that The carrier also includes one or more of cationic lipids or ionizable lipids, neutral lipids, and steroidal lipids.
13. The composition according to claim 8, characterized in that The carrier also includes but is not limited to cationic lipids or ionizable lipids, neutral lipids and steroidal lipids, and the molar ratio of the cationic lipids or ionizable lipids, the polymer lipids, the neutral lipids and the steroidal lipids is (30-80): (0.2-5): (5-20): (30-50).
14. The composition according to claim 8, characterized in that The composition may further comprise one or more pharmaceutically acceptable excipients or diluents.
15. Use of the lipid compound, conjugate or composition according to any one of claims 1 to 14 in the preparation of nucleic acid drugs, gene vaccines, polypeptides, antibodies, proteins, carbohydrates and small molecule drugs.
16. The lipid compound, conjugate or composition according to any one of claims 1 to 14 is used in the preparation of nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, wherein the composition is lipid nanoparticles having a particle size of 20 to 1000 nm.
17. A composition for preparing nucleic acid drugs, gene vaccines, polypeptides, proteins, antibodies and small molecule drugs, comprising a nucleic acid and a composition for encapsulating the nucleic acid, wherein the composition is a lipid nanoparticle, wherein each individual lipid nanoparticle comprises a plurality of lipid components, wherein one or two lipid components are bile acid-based lipid compounds, including compounds thereof or pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, chelates, non-covalent compounds or prodrugs thereof, and wherein the lipid nanoparticle has a nucleic acid encapsulation ratio of at least 70%.
18. A method for preparing the composition of claim 16, wherein the lipid nanoparticles are formed by mixing an mRNA solution with a lipid solution comprising a polymer lipid compound according to any one of claims 1 to 7 or a lipid solution of a conjugate thereof, wherein the medium of the mRNA solution is HEPES (hydroxyethylpiperazine ethanesulfonic acid buffer), sodium phosphate, sodium acetate, ammonium sulfate, sodium bicarbonate or sodium citrate; the medium of the lipid solution is ethanol, isopropanol or dimethyl sulfoxide; wherein the lipid nanoparticles are further purified by dialysis or ultrafiltration.
19. The composition according to claim 14, further comprising one or more of a buffer, a carbohydrate, mannitol, a protein, a polypeptide or an amino acid, an antioxidant, an antibacterial agent, a chelating agent, and an adjuvant.
20. The composition according to claim 13, wherein the administration method comprises intravenous injection, intramuscular injection, subcutaneous injection, intradermal injection, intratumor injection, ocular administration, ear administration, nasal administration, oral administration, anal administration or vaginal administration.
21. The composition according to claim 13, wherein the administration subject comprises mammals such as cattle, horses, mules, donkeys, camels, pigs, sheep, dogs, foxes or rabbits, birds such as chickens, ducks, geese or pigeons, fish, non-human primates or humans.
22. A polymer lipid compound, characterized in that The polymer lipid compound is a lipid based on bile acid or its derivatives, or the polymer lipid compound is a pharmaceutically acceptable salt, prodrug or stereoisomer of a lipid based on bile acid or its derivatives, and the polymer lipid compound has the following general structure: R1 = hydrogen atom, alkane, alkene, alkyne, substituted carbonyl, Alkanes containing nitrogen atoms, alkenes containing nitrogen atoms, alkanes containing oxygen atoms R2 = hydrogen atom, alkyl group, alkene, alkyne, substituted carbonyl group, alkane containing nitrogen atom, alkene containing nitrogen atom R3=hydroxyl group, chlorine atom, alkane, alkene, alkyne R4=hydrogen atom, small molecule, antibody, peptide, protein, nucleic acid, carbohydrate X = PEG (polyethylene glycol), polysarcosine derivatives, chitosan derivatives, dextran, polylactic acid, polyamino acid-modified phosphatidylethanolamine, phosphatidic acid, ceramide, dialkylamine, diacylglycerol, dialkylglycerol L1, L2 = identical or different, linear / branched alkyl chains or heterocyclic compounds, with one or more of amino, carboxyl, hydroxyl, thiol, sulfate, sulfonic acid, phosphoric acid, and carbonate at both ends.
23. The polymer lipid compound according to claim 22, characterized in that The cholic acid or its derivative is optionally one or more of 3β-hydroxy-DS-cholic acid, lithocholic acid, deoxycholic acid, 5β-cholic acid, dehydrocholic acid, cholic acid, hyodeoxycholic acid, hyodeoxycholic acid methyl ester, sodium taurohyodeoxycholate, sodium dehydrocholate, sodium deoxyglycocholate, sodium taurodeoxycholate, taurocholic acid-3-sulfate disodium salt, and sodium taurolithocholic acid.
24. The polymer lipid compound according to claim 23, characterized in that The lipid compound is lithocholic acid or its derivatives.
Citation Information
Patent Citations
Cholic acid coupling compound, preparation method and application thereof
CN101798332A
Lipid compositions
CN102421417A
Flexible liposome containing drugs and preparation method thereof
CN109998994A
Cholic acid derivative as well as preparation method and application thereof
CN110804082A
Cationic lipid compound, composition containing same and application
CN113018449A
